Routine vaccines across the life span, 2003

Journal of Family Practice

Volumn 52, Issue 1 SUPPL., 2003, Pages

  Kent Zimmerman, Richard ^a   Middleton, Donald B ^a   Burns, Ilene Timko ^a   Clover, Richard D ^a  

^a NONE

Author keywords

Bacterial vaccines; Hepatitis B vaccine; Influenza vaccine; Measles vaccine; Pertussis vaccine; Poliovirus vaccine; Varicella vaccine

Indexed keywords

ACELLULAR VACCINE; CB 2; CHICKENPOX VACCINE; CLL 4F2; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PENUMOVAX 23; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SKB 3P; STAPHYLOCOCCUS AUREUS VACCINE; UNCLASSIFIED DRUG; VACCINE; VARICELLA ZOSTER VACCINE;

ARTHRALGIA; ARTHRITIS; CHICKENPOX; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; EDEMA; ERYTHEMA; FATIGUE; FEBRILE CONVULSION; FEVER; HEADACHE; HEPATITIS B; HUMAN; HYPERSENSITIVITY REACTION; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INJECTION PAIN; LYMPHADENOPATHY; MALAISE; MEASLES; MUMPS; MYALGIA; NEUROLOGIC DISEASE; PAIN; PERTUSSIS; POLIOMYELITIS; REVIEW; RUBELLA; SEIZURE; THROMBOCYTOPENIA; VACCINATION;

EID: 0037235057     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Moyer LA, Mast EE. Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am J Prev Med 1994;10(Suppl):45-55.
2. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92
3. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-1222.
4. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Eviron Microbiol 1956;32:572-574.
5. Franks AL, Berg CJ, Kane MA. et al Hepatitis B virus infection among children born in the United States to Southeast Asian refugees N Engl J Med 1989;321:1301-1305. Erratum: N Engl J Med 1990;322:280.
6. Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. Pediatrics 1992;89:269-273
7. Craxi A, Tine F, Vinci M, et al. Transmission of hepatitis B and hepatitis delta viruses in the households of chronic hepatitis B surface antigen carriers: a regression analysis of indicators of risk. Am J Epidemiol 1991:134:641-650.
8. Hayashi J, Kashiwagi S, Nomura H, Kajiyama W, Ikematsu H. Hepatitis B virus transmission in nursery schools. Am J Epidemiol 1987;125:492-498.
9. Kashiwagi S, Hayashi J, Ikematsu H, T et al. Transmission of hepatitis B virus among siblings. Am J Epidemiol 1984;120:617-625
10. Summers PR, Biswas MK, Pastorek JG, Pernoll ML, Smith LG. Bean BE. The pregnant hepatitis B carrier: evidence favoring comprehensive antepartum screening. Obstet Gynecol 1987;69:701-704.
11. , Kumar ML, Dawson NW, McCullough AJ, et al. Should all pregnant women be screened for hepatitis B? Ann Intern Med 1987;107:273-277.
12. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993;118:298-306.
13. Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA 1995;274:1201-1208.
14. Ascherio A, Zhang SM, Hernan MA, et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327-332.
15. Centers for Disease Control and Prevention. Recommended childhood immunization schedule - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:31-33.
16. US Preventive Services Task Force. Guide to clinical preventive services. Baltimore, MD: Williams & Wilkins, 1996.
17. West DJ, Margolis HS. Prevention of hepatitis B virus infection in the United States: a pediatric perspective. Pediatr Infect Dis J 1992;11:866-874.
18. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States. 1980-1989. Clin Infect Dis 1992;14:708-719.
19. Centers for Disease Control and Prevention Epidemiology and prevention of vaccine-preventable diseases - the Pink Book Atlanta, GA: US Department of Health and Human Services, 1997.
20. Blennow M, Granstrom M. Long term serologic follow-up after pertussis immunization. Pediatr Infect Dis J 1990;9:21-26.
21. Centers for Disease Control and Prevention. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. MMWR Morb Mortal Wkly Rep 1997;46:1-25.
22. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-348.
23. Schmitt HJ, von Konig CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
24. Trollfors B, Taranger J, Lagergard T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;338:1045-1050.
25. Morgan CM, Blumberg DA, Cherry JD, et al. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. Am J Dis Child 1990;144:41-45
26. Pichichero ME, Badgett JT, Rodgers GC Jr., McLinn S, Trevino-Scatterday B, Nelson JD. Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatr Infect Dis J 1987;6:352-363.
27. Aoyama T, Hagiwara S, Murase Y, Kato T, Iwata T. Adverse reactions and antibody responses to acellular pertussis vaccine. J Pediatr 1986;109:925-930.
28. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-566
29. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981;68:650-660.
30. Institute of Medicine, Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines, Howson CP, Howe CJ, Fineberg HV. Adverse Effects of Pertussis and Rubella Vaccines: A Report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Washington, DC: National Academy Press, 1991.
31. Centers for Disease Control and Prevention Update: vaccine side effects, adverse reactions, contraindications, and precautions-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45(RR-12):1-35.
32. Onorato JM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 1992;267:2745-2749.
33. Nelson JD. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child 1978;132:371-373.
34. Volk VK, Gottshall RY, Anderson HD, Top FH, Bunney WE, Gilbert MG. Antibody response to booster dose of diphtheria and tetanus toxoids. Public Health Rep 1963;78:161-164.
35. Linnemann CC Jr, Ramundo N, Perlstein PH, et al. Use of pertussis vaccine in an epidemic involving hospital staff. Lancet 1975;2:540-543.
36. American College of Physicians Task Force on Adult Immunization, Infectious Diseases Society of America. Guide for adult immunization. Philadelphia, PA: American College of Physicians, 1994.
37. Morbidity Recommendations for use of haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and haemophilus b vaccine. MMWR Recomm Rep 1993;42(RR-13):1-15
38. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Atlanta, GA: Public Health Foundation, 2002:1-266.
39. Centers for Disease Control and Prevention. Progress toward elimination of Haemopbilus influenzae type b disease among infants and children - United States, 1998-2000. MMWR Morb Mortal Wkly Rep 2002;51:234-237.
40. Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b disease among infant and children 1987-1997. MMWR Morb Mortal Wk]y Rep 1998;47:993-998.
41. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Streptococcus pneumoniae, 1998. Available at: www.cdc.gov/nci-dod/dbmd/abcs/suvreports/spneu98.pdf and www.cdc.gov/nci-dod/dbmd/diseaseinfo/drugresisstreppneum_t.htm.
42. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49:1-38.
43. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997;337:970-976.
44. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 1999;103:e28.
45. Nuorti JP, Butler JC, Fartey MM, et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 2000;342:681-689.
46. Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers. Arch Pediatr Adolesc Med 1999;153:495-502.
47. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1835.
48. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-137.
49. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM 197 in United States infants. Pediatrics 1998;101:604-611.
50. Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999;18:757-763.
51. Butler JC, Brieman RF, Lipman HB, Hoffman J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis 1995;171:885-889.
52. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195.
53. Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infarcts and young children. JAMA 2000;283:1460-1468.
54. American Academy of Pediatrics Committee on Infectious Diseases. Policy Statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000;106:362-366.
55. American Academy of Family Physicians. Recommendation for Pneumococcal Conjugate Immunization, 2001. Available at: www.aafp.org/policy/camp/24.html. Accessed on: April 11, 2001.
56. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-25.
57. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication - the Americas, 1994. MMWR Morb Mortal Wkly Rep 1994;43:720.
58. Centers for Disease Control and Prevention. Progress toward global eradication of poliomyelitis. MMWR Morb Mortal Wkly Rep 1997;46:579-584.
59. Thorns ML, Bodnar PZ, O'Donovan JC, Gouel EG, Walcher JR, Halsey NA. Parental knowledge and choice regarding live and inactivated poliovirus vaccines. Arch Pediatr Adolesc Med 1997;151:809-812.
60. Desai S, Kolasa M, Bisgard K, Prevots R, Dibling K. Is the new poliovirus immunization recommendation acceptable to parents? Abstracts of the 32nd National Immunization Conference; Atlanta, GA; July 21-24, 1998.
61. American Academy of Pediatrics. Measles. In: Pickering LK, ed. 2000 Red book: report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2000:385-396.
62. Centers for Disease Control and Prevention. Notice to readers: Final 2001 reports of selected notifiable diseases. MMWR Morb Mortal Wkly Rep 2002;51:710,723-730 Available at: www cdc.gov/mmwr/preview/mmwrhtml/mm5132a6.htm. Accessed on December 13, 2002.
63. American Academy of Pediatrics. Mumps. In: Pickering LK, ed. 2000 Red book: report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2000:405-408.
64. American Academy of Pediatrics. Rubella. In: Pickering LK, ed. 2000 Red book: report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2000:495-500.
65. Primer on the rheumatic diseases. Atlanta, GA: Arthritis Foundation, 2001:266.
66. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines: evidence bearing on casuality. Washington, DC: National Academy Press, 1994.
67. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable disease. Atlanta, GA: US Department of Health and Human Services, 2002;110.
68. Arvin AM. Varicella vaccine - the first six years. N Engl J Med 2001;344:1007-1009.
69. American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, ed. 2000 Red book: report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2000:624-638.
70. Whatton M, Fehrs LJ, Stroup NE, et al. The health impact of varicella in the 1980s. Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; Atlanta, GA; October 21-24, 1990.
71. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-381.
72. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45:1-36.
73. Vazquez M, LaRussa PS, Gershon AA, Steinberg SPO, Freudigman K, Shapiro ED. The effectiveness of varicella vaccine in clinical practice. N Engl J Med 2001;955-960
74. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994;140:81-104.
75. Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994;94:524-526.
76. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45(RR-11):1-36.
77. Asano Y, Nakayama H, Yazaki T, Kato R, Hirose S. Protection against varicella in family contacts by immediate inoculation with varicella vaccine. Pediatrics 1977;59:3-7
78. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J 1998;17:256-257.
79. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986;78:748-756.
80. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48:1-37.
81. McCaustland KA, Bond WW, Bradley DW, Ebert JW, Maynard JE. Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol 1982;16:957-958.
82. Lemon SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang 1994;67:19-23.
83. Centers for Disease Control and Prevention Hepatitis surveillance report no. 56. Atlanta, GA: US Department of Health and Human Services, Public Health Service, 1996.
84. Bell BP, Shapiro CS, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J Infect Dis 1998;178:1579-1584.
85. Krugman S, Giles JP. Viral hepatitis new light on an old disease. JAMA 1970;212:1019-1029.
86. Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers: a communitywide assessment. N Engl J Med 1980;302:1222-1227.
87. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infection in adults. Am J Epidemiol 1985;122:226-233
88. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med 1998;128:111-114.
89. Clemens R, Safary A, Hepburn A, Roche C, Stanbury WJ, Andre FE. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171:S44-S49.
90. McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and native and non-native adults. J Infect Dis 1995;171:676-679.
91. Van Herck K, Van Damme P, Thoelen S. A high potency inactivated hepatitis A vaccine: long term follow-up [Abstract A02]. Final program/book of abstracts. 6th Conference of the International Society of Travel Medicine. Stone Mountain, GA: 1999.
92. Werzberger A, Mensch B, Taddeo C, et al. 6-year follow-up of children and adolescents who participated in an efficacy trial of VAQTA (hepatitis A vaccine, inactivated, Merck) [Abstract 078]. Conference abstracts of the 32nd National Immunization Conference. Atlanta, GA: CDC; July 21-24, 1998.
93. Wiedermann G, Kindi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after a single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop 1998;69:121-125.
94. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002:51:1-24.
95. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997;87:1944-1950.
96. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effect of influenza on hospitalization, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000;342:225-231.
97. Neuzil KM, Wright PF, Mitchel EF, Griffin MR. Burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000;137:856-864.
98. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-239.
99. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000;283:499-505.
100. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999;340:260-264.
101. Sullivan KM, Monto AS, Longini IM, Jr. Estimates of the US health impact of influenza. Am J Public Health 1993;83:1712-1716.
102. Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986;4:38-44.
103. Meiklejohn G, Hall H. Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 1987;35:742-746.
104. Goodman RA, Orenstein WA, Munro TF, Smith SC, Sikes RK. Impact of influenza A in a nursing home. JAMA 1982;247:1451-1453
105. Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev Infect Dis 1980;2:408-420.
106. Glezen WT, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr Infect Dis J 1997;16:1065-1068.
107. Glezen WP, Couch RB, Taber LH, et al. Epidemiologic observations of influenza B virus infections in Houston, Texas, 1976-1977. Am J Epidemiol 1980;111:13-22.
108. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970;122:16-25.
109. Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993;168:881-887.
110. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating school-children against influenza. N Engl J Med 2001;344:889-896.
111. Nichols KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-893.
112. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization from pneumonia in the elderly. Am J Epidemiol 1992;136:296-307.
113. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccine in Manitoba. JAMA 1993;270:1956-1961. Erratum, JAMA 1994;271:1578.
114. Barker WH, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. Options for the control of influenza. New York, NY: Allan R. Liss, 1986;169-182.
115. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A metaanalysis and review of the literature. Ann Intern Med 1995;123:518-527.
116. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994;272:1661-1665.
117. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg TL. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784.
118. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost effectiveness and public policy. JAMA 1983;249:3189-3195.
119. Centers for Disease Control and Prevention. Final results: Medicare influenza vaccine demonstration - selected states. 1988-1992. MMWR Morb Mortal Wkly Rep 1993;42:601-604.
120. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5:659-671.
121. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000;106:973-976.
122. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999;103:1-5.
123. Luce BR, Zangwill K, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001;108:e24-e38.
124. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-123.
125. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory. Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-24.
126. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of the drug-resistant Streptococcus pneumoniae (DRSP): a strategy from the DRSP working group. JAMA 1996;275:206-209.
127. Overturf GD, Committee on Infectious Diseases. Technical Report: Prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis (RE9960). Pediatrics 2000;106:367-376.
128. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. 7th ed. Atlanta, GA: US Department of Health and Human Services, 2002:205-217.
129. American Academy of Pediatrics Pneumococcal infections. In: Pickering LK, ed. 2000 Red book: report of the Committee on Infectious Diseases Elk Grove Village, IL: American Academy of Pediatrics, 2000:452-460.
130. American Hospital Formulary Service. Pneumococcal vaccine, polyvalent. In: McEvoy GK, ed. Drug information 2001. Bethesda, MD: American Hospital Formulary Service, 2001:3261-3265.
131. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Fam Med 1994;154:2666-2677.
132. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 Western European countries. Clin Infect Dis 2000;31:444-450.
133. Jackson LA, Benson P, Sneller VP. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-244.
134. Gardner P, Eickhoff T, Poland GA, et al. Aduly immunizations. Ann Intern Med 1996;124:35-40.
135. Fedson DS, Harward MP, Reid RA, Kaiser DI. Hospital-based pneumococcal immunization. Epidemiologic rationale from the Shenandoah study. JAMA 1990;264:1117-1122.